Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review.

Details

Serval ID
serval:BIB_E1A4CE5FA5F8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review.
Journal
Cancers
Author(s)
Raemy A., May L., Sala N., Diezi M., Beck-Popovic M., Broome M.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
07/06/2024
Peer-reviewed
Oui
Volume
16
Number
12
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy. We present a case of a 15-year-old girl with ameloblastoma successfully treated with targeted therapy and review the literature with this question: Is anti-MAPK targeted therapy safe and effective for treating ameloblastoma? This systematic review was registered in PROSPERO, adhered to PRISMA guidelines, and searched multiple databases up to December 2023, identifying 13 relevant studies out of 647 records, covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes. Side effects were mostly mild to moderate. This study presents anti-MAPK therapy as a significant shift from invasive surgical treatments, potentially enhancing life quality and clinical outcomes by offering a less invasive yet effective treatment alternative. This approach could signify a breakthrough in managing this challenging tumor, emphasizing the need for further research into molecular-targeted therapies.
Keywords
adverse effect, ameloblastoma, anti-BRAF/MEK, effectiveness, targeted therapy
Pubmed
Web of science
Open Access
Yes
Create date
05/07/2024 11:01
Last modification date
06/07/2024 7:06
Usage data